Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Anaplastic Lymphoma Kinase (ALK) rearranged Non-Small Cell Lung Cancers (NSCLCs) are a distinct patient subgroup with unique features.
• Patients with ALK-rearranged NSCLCs show significant responses to Crizotinib, an ALK tyrosine kinase inhibitor.
• Central Nervous System (CNS) activity of Crizotinib is less effective than extracranial activity, leading to increased CNS involvement with prolonged survival.

Purpose of the Study:

• To review the CNS activity of Crizotinib and novel ALK inhibitors in ALK-rearranged NSCLCs.
• To evaluate current therapeutic strategies for CNS involvement in this patient subgroup.
• To provide insights into future treatment approaches for ALK-positive NSCLCs with CNS disease.

Main Methods:

• Literature review summarizing existing data on CNS activity of ALK inhibitors.
• Evaluation of strengths and weaknesses of current therapeutic strategies.
• Analysis of ongoing clinical trials and future directions.

Main Results:

• Crizotinib demonstrates limited CNS penetration and efficacy compared to extracranial sites.
• Novel generation ALK inhibitors are being developed to enhance CNS penetration and efficacy.
• CNS involvement is a growing clinical challenge in ALK-rearranged NSCLC due to improved survival.

Conclusions:

• Ongoing head-to-head trials will determine optimal treatment sequences for ALK-rearranged NSCLCs.
• Further clinical trials with novel ALK inhibitors are needed to establish the best approach for CNS involvement.
• Improved CNS-penetrant ALK inhibitors are crucial for managing brain metastases in ALK-positive NSCLC.